The results revealed that in HPV-positive HNSCC cases, p16-negative patients had an HR of 2.14 (95% CI: 1.62-2.83) for tumors, significantly higher than the reference group of p16-positive or HPV-positive tumors after adjusting for age and tumor stage. Here, CDKN2A is linked to neoplasm.